文献速递鼻科

温度控制射频消融治疗慢性鼻炎:一项前瞻性多中心试验的两年结局

Temperature-controlled radiofrequency ablation for the treatment of chronic rhinitis: Two-year outcomes from a prospective multicenter trial.
PubMed 文献 · Int Forum Allergy Rhinol · 2024-01-24

这项前瞻性、多中心、患者盲法随机对照试验将初始活性治疗组与交叉对照组患者合并,评估后鼻神经温度控制射频消融对慢性鼻炎的两年疗效。两年时鼻部症状总分较基线平均降低5.3分(95%CI -5.8至-4.8,p<0.001),应答率87.3%,未报告器械或操作相关严重不良事件。

要点

  • 两年时鼻部症状总分较基线平均降低5.3分(95%CI -5.8至-4.8),改善64.6%。
  • 两年应答率(鼻部症状总分改善≥30%)为87.3%(95%CI 78.0-93.8)。
  • 基线使用慢性鼻炎药物的56例中,25例(44.6%)在两年时停用全部药物或停用/减少至少一类药物。

核心结论

  • 后鼻神经温度控制射频消融安全,在两年内持续显著降低慢性鼻炎症状负担,并大幅减少伴随用药负担。

研究设计与样本

  • 前瞻性、多中心、患者盲法随机对照试验,将初始活性治疗组与主要终点后交叉的对照组患者合并为单组进行两年随访分析。
  • 基线鼻部症状总分均值8.2(95%CI 7.9-8.6;N=104),两年时随访N=79。

主要发现

  • 两年时鼻部症状总分平均变化为-5.3(95%CI -5.8至-4.8;p<0.001;改善64.6%)。
  • 两年应答率(鼻部症状总分改善≥30%)为87.3%(95%CI 78.0-93.8)。
  • 鼻部症状总分四个成分(流涕、鼻塞、喷嚏、鼻痒)均较基线显著改善,其中流涕和鼻塞改善最明显;后鼻滴漏和咳嗽症状也显著改善。
  • 两年时81.0%(95%CI 70.6-89.0)报告微型鼻结膜炎生活质量问卷评分改善≥0.4分,达到最小临床重要差异。
  • 基线使用慢性鼻炎药物的56例中,两年时25/56(44.6%)停用全部药物(7/56[12.5%])或停用/减少至少一类药物(18/56[32.1%])。

关键数值与推荐

  • 敏感性分析:对14例失访/退出/死亡但有随访数据的患者采用末次观测值结转,对9例接受额外鼻部手术的患者按无应答处理,得到两年应答率79.4%(95%CI 70.3-86.8)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Minimally invasive temperature-controlled radiofrequency (TCRF) ablation of the posterior nasal nerve (PNN) demonstrated a significant larger treatment effect on the symptom burden of chronic rhinitis patients than a sham control (no energy delivery) at the 3-month primary endpoint of this trial. METHODS: Two-year posttreatment outcomes for patients treated in a prospective, multicenter, patient-blinded randomized controlled trial were determined by combining the index active treatment-arm and index control-arm crossover patients into a single group (after the primary endpoint) to evaluate the treatment effect durability and long-term effects on concomitant chronic rhinitis medication usage. RESULTS: The mean baseline reflective total nasal symptom score (rTNSS) was 8.2 (95% confidence interval [CI], 7.9-8.6; N = 104). At 2 years (N = 79), the mean change in rTNSS was -5.3 (95% CI, -5.8 to -4.8; p < 0.001; 64.6% improvement). The 2-year responder rate (≥30% improvement in rTNSS) was 87.3% (95% CI, 78.0-93.8). All four components of the rTNSS (rhinorrhea, congestion, sneezing, and nasal itching) showed significant improvement over baseline, with rhinorrhea and congestion showing the most improvement. Postnasal drip and cough symptoms were also significantly improved. At 2 years, 81.0% (95% CI, 70.6-89.0) reported a minimal clinically important difference of ≥0.4-point improvement in the mini-rhinoconjunctivitis quality of life questionnaire score. Of 56 patients using chronic rhinitis medications at baseline, 25 of 56 (44.6%) either stopped all medication use (7/56 [12.5%]) or stopped/decreased (18/56 [32.1%]) use of ≥1 medication class at 2 years. No serious adverse events related to the device/procedure were reported over 2 years. To determine the potential effect of patients who left the trial over 2 years on the responder rate, the responder statuses of the 14 patients with follow-up data who were lost to follow-up/withdrew/died were imputed by the last observation carried forward and the responder statuses of all nine patients who had an additional nasal procedure were imputed to nonresponder, resulting in a 2-year responder rate of 79.4% (95% CI, 70.3-86.8). CONCLUSION: TCRF ablation of the PNN is safe and resulted in a significant and sustained reduction in chronic rhinitis symptom burden through 2 years and a substantial reduction in concomitant medication burden.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Takashima M, Stolovitzky JP, Ow RA, et al. Temperature-controlled radiofrequency ablation for the treatment of chronic rhinitis: Two-year outcomes from a prospective multicenter trial. Int Forum Allergy Rhinol. 2024. PMID: 38266636. doi:10.1002/alr.23315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。